About Us

Anand Varadan

Chief Commercial Officer

Anand Varadan joined Chiasma as Executive Vice President, Chief Commercial Officer in April 2020 and previously served as our Chief Commercial Officer from August 2015 to June 2016. Most recently, Mr. Varadan provided commercial and strategic consultancy services to the Company as well as a variety of other biotech companies and investors through his consulting firm, Ignition Insights, LLC, which he has operated since June 2016. From June 2018 to July 2019, Mr. Varadan served as Executive Vice President, Chief Commercial Officer of Karyopharm Therapeutics, Inc. (NASDAQ: KPTI), an oncology-focused pharmaceutical company. From January 1999 to July 2015, he served in a progression of commercial leadership and general management roles at Amgen Inc. (NASDAQ: AMGN), a biopharmaceutical company, including Vice President, Inflammation and Nephrology Business Unit from April 2014 to July 2015 and Vice President/General Manager, Amgen Canada from September 2011 to April 2014. Prior to Amgen, Mr. Varadan was a brand manager at Procter and Gamble Company. Mr. Varadan received an M.B.A. from the Simon Business School at the University of Rochester and a B.A. in Zoology from The George Washington University.

Raj Kannan

Chief Executive Officer & President

Raj Kannan was named Chief Executive Officer in June 2019. Mr. Kannan brings over 25 years of pharma industry experience. He has held a variety of roles from field sales to leading global business franchises. Mr. Kannan has led and supported multiple successful launches across therapeutic areas both in the U.S. and globally. Prior to joining Chiasma, Mr. Kannan served as the Chief Commercial Officer at Kiniksa Pharmaceuticals since July 2018. In that role, he was responsible for building and leading the company’s commercial operations, including sales, marketing, business analytics and market-access functions. Prior to Kiniksa, Mr. Kannan served as the Global Head of the Neurology and Immunology business franchise at Merck KGaA, where he was responsible for $2B in annual revenues and for providing the strategic direction for assets in clinical development. Prior to Merck KGaA, Mr. Kannan spent ten years at Boehringer Ingelheim in roles of increasing responsibility in the U.S., Canada, and in Germany, including the role of Global Marketing Head of the Cardiovascular Franchise, where he was responsible for over $3.5B in annual revenues.

John Doyle

Chief Financial Officer

John Doyle joined Chiasma as Senior Vice President, Chief Financial Officer in January 2021. Mr. Doyle brings over 18 years of strategic and operational finance experience. Most recently, Mr. Doyle served as the Vice President of Finance and Investor Relations at Verastem Oncology. In that role, he managed the company’s finance and communications strategy through multiple transactions and corporate events. During his time at Verastem the company received FDA Approval and commercially launched COPIKTRA™ in the U.S., which ultimately led to the sale of the asset in a deal worth ~$300M. Additionally, the company raised over $350M through various financing and business development activities to fund the commercial launch and to support the development of a newly acquired asset. Prior to Verastem, Mr. Doyle was Head of Financial Planning and Analysis at SimpliVity Corp. and was the finance lead for the company’s $650M acquisition by Hewlett Packard Enterprises. Prior to SimpliVity, Mr. Doyle held several roles of increasing responsibility within Finance in the Medical Device and Technology sectors. Mr. Doyle earned his B.S. in Finance from the University of Massachusetts.

William Ludlam, M.D., Ph.D.

Senior VP Clinical Development & Medical Affairs

William Ludlam, M.D., Ph.D., is our Senior Vice President of Clinical Development and Medical Affairs. He joined Chiasma as VP Medical Affairs in August 2015. Dr. Ludlam came to us from Novartis Pharmaceuticals, where he was Senior Medical Director, Pituitary Disorders, U.S. Oncology CDMA, Rare Diseases. Earlier, he served as Medical Director of the Seattle Pituitary Center, Neuroscience Institute, Swedish Medical Center, and as Medical Director of the Pituitary Unit, Oregon Health and Science University. He has also held academic appointments at the Oregon Health and Science University. He is a member of the Endocrine Society, the Pituitary Society, and the American Association of Clinical Endocrinologists, and serves on the Hormone Health Network of the Endocrine Society. Dr. Ludlam earned his M.S. and Ph.D. from the Sue Golding Graduate Division of the Albert Einstein College of Medicine and his M.D. from the Albert Einstein College of Medicine.

Gary Patou, M.D.

Strategic Clinical Advisor

Gary Patou, M.D., has headed up our clinical efforts since August 2014. He also has been Chief Medical Officer of True North Therapeutics, Inc. since November 2016. Dr. Patou previously served as Chief Medical Officer for Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX), or Pacira, a specialty pharmaceutical company. In addition, he has been a Managing Director at MPM Capital, Inc., or MPM, a venture capital fund focused on life sciences companies, since 2005. Prior to joining Pacira, Dr. Patou was Chief Medical Officer at Peplin Inc. from July 2006 to April 2007, Chief Medical Officer of Cerimon Pharmaceuticals, Inc. from June 2005 to June 2006, and Executive Vice President and Chief Medical Officer of Oscient Pharmaceuticals Corp. from February 2004 to April 2005 just after its merger with GeneSoft Pharmaceuticals, Inc., or GeneSoft. Before GeneSoft, Dr. Patou worked at SmithKline Beecham Pharmaceuticals, now a unit of GlaxoSmithKline, as Senior Vice President and Director, Project and Portfolio Management, managing all of the company’s pharmaceutical development projects. He also serves on the board of directors at Xenon Pharmaceuticals Inc. (NASDAQ: XENE). Dr. Patou has held a number of academic appointments at University College & Middlesex School of Medicine and received his B.Sc. from University of London and his M.D. from University College London.

David Schubert

Senior VP Regulatory & Quality

David Schubert joined Chiasma as the Senior Vice President, Regulatory and Quality in July 2020. Most recently, Mr. Schubert was Vice President of Regulatory and Quality at Stealth Biotherapeutics, a company developing mitochondrial targeted therapies for rare and common diseases. Previously, Mr. Schubert was the Vice President of Regulatory and Quality for MediVector, a company developing antiviral drug candidates that inhibit RNA polymerase for the therapeutic treatment of influenza. Prior to MediVector, Mr. Schubert served as regulatory and quality lead for several companies including Logical Therapeutics, Coley Pharmaceutical Group and Cubist Pharmaceuticals. Mr. Schubert started his professional career as a bench top and process development protein chemist at Genetics Institute. Mr. Schubert has over 30 years of experience in regulatory, quality, rare disease drug development, and process development and is a past advisor, facilitator, and presenter of DIA’s Rare Disease educational initiatives. Mr. Schubert received his B.S. in Botany from the University of New Hampshire.

John F. Thero

Director

John F. Thero joined our Board of Directors in November 2015. Mr. Thero has served as the President and Chief Executive Officer of Amarin, since 2014 after previously serving as President since November 2010 and initially as Chief Financial Officer. Mr. Thero also serves as a director of Amarin. Prior to Amarin, Mr. Thero was at ViaCell, Inc., where as Chief Financial Officer he helped guide the company to its successful sale to PerkinElmer (NYSE:PKI), and Abiomed, Inc. (NASDAQ:ABMD), where he held multiple positions, including Senior Vice President of Business Operations and Chief Financial Officer. Mr. Thero began his professional career at Arthur Andersen LLP. Mr. Thero received a B.A. in Economics and Accounting from The College of the Holy Cross. In 2019, Mr. Thero was awarded EY’s Entrepreneur of the Year for Life Sciences.

John A. Scarlett, M.D.

Director

John A. Scarlett, M.D. joined our Board of Directors in February 2015. Dr. Scarlett has been Chief Executive Officer and director of Geron Corporation (NASDAQ: GERN), a biotechnology company, since September 2011 and President since January 2012 and was appointed to Chairman of the Board in December 2018. Previously, he was the President and Chief Executive Officer of Proteolix, Inc., a biotechnology company that merged with Onyx Pharmaceuticals, Inc. (NASDAQ: ONXX) in October 2009, and a founder and Chief Executive Officer of Tercica, Inc. (NASDAQ: TRCA), which was acquired by Ipsen S.A. (EPN: IPN) in 2008. From 1993 to 2001, Dr. Scarlett was also the founder and Chief Executive Officer of Sensus Drug Development Corporation, which was acquired by Pharmacia Corporation in 2001, and co-founded Covance Biotechnology Services, Inc., a contract biologics manufacturing and process development business that was acquired by Akzo Nobel’s (OTCMKTS: AKZOY) Diosynth Division in 2001. Earlier in his career, he worked for McNeil Pharmaceuticals Inc., a subsidiary of Johnson & Johnson (NYSE: JNJ), and Novo Nordisk Inc. (NYSE: NVO). Dr. Scarlett currently serves on the board of Cytomx Therapeutics, Inc. (NASDAQ: CTMX). He received his B.A. from Earlham College and his M.D. from the University of Chicago, Pritzker School of Medicine. He completed his training in Internal Medicine at the Hospital of the University of Pennsylvania and his fellowship in Endocrinology and Metabolism at the University of Colorado Health Sciences Center.

Scott Minick

Director

Scott Minick joined our Board of Directors in October 2007. From January 2010 to March 2015, Mr. Minick served as President and Chief Executive Officer of BIND Therapeutics, Inc. (NASDAQ: BIND), or BIND, a biopharmaceutical company. From 1998 to 2010, Mr. Minick was Managing Director of ARCH Venture Partners, or ARCH, and from 2010 to the present he has been Venture Partner of ARCH, where he was instrumental in the startup, development and financing of numerous ARCH portfolio companies, including BIND and Chiasma. From 1995 to 1998, Mr. Minick was Director, President and Chief Operating Officer of SEQUUS Pharmaceuticals, Inc. (NASDAQ:SEQU), a biopharmaceutical company that was acquired by ALZA Corporation. Mr. Minick was formerly an executive at Baxter International, Inc. (NYSE: BAX) and Eli Lilly & Company (NYSE: LLY). He serves as a member of the board of directors of Alzheon, Inc. and Aira Tech Corp., served as a member of the board of directors of BIND from 2007 to 2015 and is a trustee of Beth Israel Deaconess Medical Center. Mr. Minick received his postgraduate training in neurobiology at the Salk Institute, an M.B.A. from Northwestern University, and a B.A. from the University of California, San Diego.

Roni Mamluk, Ph.D.

Director

Roni Mamluk, Ph.D. joined our Board of Directors in June 2017. Dr. Mamluk currently serves as chief executive officer of Ayala Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company dedicated to developing targeted cancer therapies for people living with genetically defined cancers. She served as our Chief Development Officer from March 2015 to March 2017 and has served as a director of Chiasma (Israel) Ltd. since April 2017. Dr. Mamluk served as our Chief Executive Officer from April 2013 to March 2015 and held various roles in the Company from 2006 to April 2013, including Chief Operating Officer and Vice President, Research and Development. She also served as a member of our Board of Directors from April 2013 to March 2015. Prior to joining us, Dr. Mamluk established and led nonclinical research and development at Adnexus Therapeutics, Inc. Dr. Mamluk received her B.A. and Ph.D. from the Hebrew University. She completed her post-doctoral fellowship at Children’s Hospital/Harvard Medical School in the field of angiogenesis.

Bard Geesaman, M.D., Ph.D.

Director

Bard Geesaman, M.D., Ph.D. joined our Board of Directors in 2004. Dr. Geesaman was at MPM Capital for over a decade before leaving in December 2018. He has broad experience investing, operating and facilitating business development globally, including in Japan, China and Israel. Prior to joining MPM, Dr. Geesaman founded Catalyst Medical Solutions, a medical documentation and billing eHealth company in Boston where he served as the Chief Technology Officer through the company’s acquisition. After Catalyst, Dr. Geesaman joined Centagenetix, an MPM-founded company exploring the genetics of successful aging. In 2006, Dr. Geesaman joined MPM as a Venture Partner with a major focus on founding Solasia Pharmaceuticals, based in Tokyo, Japan which listed on the Tokyo Mothers exchange in March 2017. Dr. Geesaman is also the co-founder and a board member of MPM healthcare IT startup TriNetX (big data analytics for clinical trials). Dr. Geesaman is passionate about innovation in health care, and in 2008 took a two-year sabbatical from MPM to do non-profit work in Los Angeles at the X-Prize Foundation, where he worked on alternative models for motivating life sciences innovation. Dr. Geesaman became board certified in Internal Medicine in 2000, after completing a Clinical Fellowship at the Massachusetts General Hospital. He received his Ph.D. from MIT, an M.D. from Harvard Medical School and a B.S. from University of California, Berkeley.

Todd Foley

Director

Todd Foley joined our Board of Directors in May 2008. Mr. Foley is a managing director with MPM Capital, a venture capital firm, or MPM, which he joined in 1999. Prior to joining MPM, Mr. Foley worked in business development at Genentech and in management consulting with Arthur D. Little. At MPM, Mr. Foley focuses on biotech investments and serves on a number of MPM portfolio company boards, including Rhythm Therapeutics (NASDAQ: RYTM), Repare Therapeutics, Inc., CODA Biotherapeutics Inc., Entrada Therapeutics, Inc., Iconic Therapeutics, Inc. and Tetherex Pharmaceuticals, Inc. Mr. Foley previously served on the boards of Celladon Corporation from 2012 to 2014, Proteon Therapeutics, Inc. from 2012 to 2014 and Zalicus, Inc. from 2009 to 2013. He also manages MPM’s strategic investment relationship with Novartis (NYSE: NVS), which MPM believes has been one of the industry’s longest standing and most prolific collaborations between venture capital investors and pharma, having committed $200 million to over a dozen companies in the biotech and healthcare IT space under a variety of creative joint equity/strategic deal structures. Mr. Foley received a B.S. in chemistry from the Massachusetts Institute of Technology, or MIT, and an M.B.A. from Harvard Business School.

Raj Kannan

CEO and Director

Raj Kannan became our Chief Executive Officer and joined our Board of Directors on June 17, 2019. Mr. Kannan joined our company from Kiniksa Pharmaceuticals, Ltd. (“Kiniksa”) (NASDAQ: KNSA) where he worked since July 2018 as Chief Commercial Officer. In that role, he was responsible for building and leading the company’s commercial operations, including sales, marketing, business analytics, and market access functions. Prior to Kiniksa, Mr. Kannan served as the Global Head of the Neurology and Immunology (“N&I”) business franchise at Merck KGaA, where he was responsible for $2 billion in annual revenues. In that role, he successfully led the launch of Mavenclad, an oral small molecule in multiple sclerosis. He also chaired the N&I franchise leadership team that was responsible for advancing the immunology pipeline assets, prioritizing the portfolio mix, and allocating resources across development assets. Prior to Merck KGaA, Mr. Kannan spent ten years at Boehringer Ingelheim (“Boehringer”) in roles of increasing responsibility in the U.S., Canada, and in Germany, including the role of Global Marketing Head of the Cardiovascular Franchise where he was responsible for over $3.5 billion in annual revenues. Before Boehringer, he worked for almost ten years at Merck and Co. in various roles from field sales to senior marketing manager in the U.S. Mr. Kannan has led or supported multiple successful launches across therapeutic areas both in the U.S. and globally. Mr. Kannan received a B.S. in chemistry from the University of Madras, as well as an M.B.A. from East Carolina University.

Dave Stack

Chairman of the Board

David Stack joined our Board of Directors in November 2014 as Chairman. Since 2007, Mr. Stack has served as Chief Executive Officer and Chairman of Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX). Mr. Stack was a Managing Director of MPM from 2005 to March 2017. From 2001 to 2004, he was President and Chief Executive Officer of The Medicines Company (NASDAQ: MDCO). Previously, Mr. Stack was President and General Manager at Innovex, Inc. (OTCMKTS: INVX). He was Vice President, Business Development/Marketing at Immunomedics, Inc. (NASDAQ: IMMU) from 1993 until 1995. Prior to that, Mr. Stack was with Roche Laboratories (ETR: RHO5) from 1981 until 1993, where he eventually served as Director of Business Development and Planning for Infectious Disease, Oncology, and Virology and was the Therapeutic World Leader for Infectious Disease. Mr. Stack currently serves on boards of Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) and Amarin Corporation plc (NASDAQ: AMRN), or Amarin, and Prognos AI. Mr. Stack received his B.S. from Albany College of Pharmacy and a B.S. from Siena College.

Christian J. Strasburger, M.D.

Professor of Medicine, Chief, Division of Clinical Endocrinology, Department of Medicine for Endocrinology, Diabetes and Nutritional Medicine; Charité-Universitätsmedizin, Campus Mitte; Berlin, Germany

Christian J. Strasburger, M.D., is currently Professor of Medicine and Chief of Clinical Endocrinology at the Department of Medicine of Charite-Universitätsmedizin, Campus Mitte, Berlin, Germany. Dr. Strasburger’s areas of research are pituitary disease, clinical and basic aspects of growth hormone physiology, analytical methods for the specific determination of hormone isoforms and related proteins, immune-endocrine interfaces and regulation of energy homeostasis. Previous appointments were Associate Professor of Medicine and Head of the Neuroendocrine Unit at the Medizinische Klinik Innenstadt of the Ludwig-Maximilians-University in Munich, Germany. He received training at the Department of Medicine at the Medical University of Lübeck, Germany, and as a MINERVA fellow of the Max-Planck Foundation at the Department of Hormone Research, Weizmann Institute of Science, Rehovot, Israel. Dr. Strasburger has published more than 190 original papers and served on the editorial board (1999-2007) and as the chief editor (2007-2011) of the European Journal of Endocrinology as well as on the editorial boards of GH & IGF Research and Pituitary and the Journal of Endocrinological Investigation. He serves on the council and is past-president of the Growth Hormone Research Society, is a former council member of the European Neuroendocrine Association, and of the German Endocrine Society.

Shlomo Melmed, M.D.

Senior Vice President, Academic Affairs, Dean of the Medical Faculty and Director, Burns and Allen Research Institute of Cedars-Sinai Medical Center; Los Angeles, California

Shlomo Melmed, M.B., Ch.B., M.A.C.P., F.R.C.P. received his medical degree with distinction from the University of Cape Town, School of Medicine in 1970. At Cedars-Sinai since 1980, he is now Senior Vice President for Academic Affairs, and Dean of the Medical Faculty. He is also Professor and Associate Dean of the University of California, Los Angeles (UCLA) School of Medicine, and Director of the Research Institute at Cedars-Sinai Medical Center. He holds the Helene A. And Philip E. Hixon Chair in Investigative Medicine. Dr. Melmed is a Diplomate of the American Board of Internal Medicine, certified in Endocrinology and Metabolism; a Master of the American College of Physicians; an elected member of the Association of American Physicians and the American Society of Clinical Investigation; recipient of the Endocrinology Medal of the Royal Society of Medicine; the Endocrine Society Clinical Investigator Award; the Society of Endocrinology Transatlantic Medal; Ipsen Fondation Endocrine Regulation Award; the Pituitary Society’s Lifetime Achievement Award; and is listed in Best Doctors of America. At Cedars-Sinai, Dr. Melmed has spearheaded major academic growth and development by leading building efforts, recruiting talented nationally recognized faculty leadership, establishing new programs and maintaining standards of excellence for educational programs. His executive leadership continues to maintain Cedars-Sinai as a top tier academic medical center. Dr. Melmed is the author of over 300 peer-reviewed manuscripts devoted to clinical and translational pituitary discovery and edits the classic text PITUITARY. He has received many honors and awards in recognition of his clinical and scientific leadership in the field of pituitary disease, including the Clinical Endocrinology Trust Medal of the Royal Society of Medicine (1994), the Endocrine Society Clinical Investigator Award (2004), Pituitary Society Award for Contributions to Understanding Pituitary Disease (2007), the Transatlantic Endocrinology Medal (2010), and the Fondation Ipsen Endocrine Regulation prize (2010).

Dan Thornton

VP Market Access and Patient Services

Dan Thornton re-joined Chiasma as Vice President of Market Access and Patient Services in September 2019. Mr. Thornton was Chiasma’s first commercial employee in 2015, where he led the effort to build a comprehensive patient services operation and secure coverage and reimbursement for the launch of the first oral treatment for acromegaly. He was previously with Flexion Therapeutics, where he served as the Vice President of Market Access for the launch of their novel treatment for knee osteoarthritis. Mr. Thornton has held leadership roles in the areas of market access, government affairs, reimbursement, and pricing for Shire, Targanta Therapeutics, Therion Biologics, Biogen Idec, and Johnson & Johnson. Dan holds his M.B.A. from the Wharton School and received his B.A. in Health Policy from Duke University.

Dawn Schottlandt

VP Investor Relations & Corporate Communications

Dawn Schottlandt joined Chiasma in November 2019 as Vice President of Investor Relations and Corporate Communications. Prior to joining Chiasma, Ms. Schottlandt was Vice President of Investor Relations and Corporate Communications at ArQule, a public biopharmaceutical company focused on oncology and rare diseases. She was previously the Director of Investor Relations at Thermo Fisher Scientific (NYSE: TMO), a leading life science tools company. She also worked at Elan Corporation as part of the Investor Relations team during the Tysabri launch. Ms. Schottlandt began her career on Wall Street as a buy side and sell side equity research analyst. She holds a B.S. in Finance from Boston College and is a Chartered Financial Analyst (CFA).

David Plante

VP Information Technology

David Plante re-joined Chiasma in August 2019 as Vice President of Information Technology. Previously, he had been our Senior Director, Information Technology from July 2015 to October 2016. In the three years between his roles at Chiasma he was the first Vice President of Information Technology for Karyopharm, an oncology-focused pharmaceutical company, where he built an Enterprise Application team that played an integral role in the commercialization of XPOVIO^® and Akebia Therapeutics, Inc., where he also built their information technology team and services for commercialization. Prior to joining Chiasma in 2015, Mr. Plante was the head of Information Technology for Commonwealth Care Alliance and Aegerion. He earned a B.S. in Civil Engineering at the University of Massachusetts, Lowell and a M.S. in Computer Science at the University of New Haven.

Scott McConnell, Pharm.D.

VP Medical Affairs

Scott McConnell, Pharm.D., re-joined Chiasma in July 2019 as Vice President of Medical Affairs. Previously he had been Senior Director of Medical Affairs and was responsible for the original department build at Chiasma. In the three years between his roles at Chiasma, he was an independent consultant in Medical Affairs for Kaledio Biosciences and Sr. Director, Medical Affairs at Alkermes. Prior to that he held a variety of roles leading Medical Affairs teams at Cubist Pharmaceuticals / Merck & Co. Before starting his career in medical affairs, he served as an Associate Professor at Creighton University and The University of Arkansas for Medical Sciences and had clinical practices and teaching responsibilities focused on Bone Marrow Transplant, Hematology, Oncology and Infectious Diseases. Dr. McConnell earned his Pharm.D. from Creighton University School of Pharmacy and Allied Health Professions. In addition, he completed a clinical Residency at Basset Healthcare and a Post-Doctoral Fellowship at The University of Arkansas for Medical Sciences.

Joe Lyons

Executive Director Human Resources

Joe Lyons joined Chiasma in August 2019 as our Executive Director of Human Resources. Prior to joining Chiasma, Mr. Lyons held roles of increasing responsibility from Director of Human Resources, Talent and Development to Executive Director & Head of Human Resources at Karyopharm Therapeutics. He was their first Human Resources leader, growing the organization from 50 to over 300 employees. He played a key role in building out their first commercial organization, which contributed to the successful launch of XPOVIO^®, an oral indication for Multiple Myeloma. Before his tenure at Karyopharm Mr. Lyons held senior-level HR roles at Sunovion (formerly Sepracor), Ironwood Pharmaceuticals, and Vertex pharmaceuticals. He holds a Master of Education, Integrated Studies from Cambridge College.

Ethel Koczon

VP Clinical Operations

Ethel Koczon joined Chiasma in May 2015 as our Senior Director of Clinical Operations. After over three years of service dedicated to our Phase 3 clinical trial program, she was promoted to Vice President of that same department. Prior to joining Chiasma, she held similar positions at MEI Pharma, Intelikine (acquired by Takeda/Millenium in 2012), Salmedix (acquired by Cephalon in 2005), Ionis Pharmaceuticals (formerly Isis), and the CRO, IBRD/Rostrum. Ms. Koczon’s extensive background includes the role of Partner and Chief Operating Officer of Exact Clinical Research Services, a niche CRO serving start-up biotechs. She began her career in Development as a Research Scientist at Johnson & Johnson. In addition, she taught Clinical Trial Design and Management courses for the USCD Extension Program. Ms. Koczon holds a B.A. in Biology from the University of California, San Diego and Medical Technologist, ASCP from Scripps, CA.

Shoshie Katz

VP Quality Assurance & Regulatory Affairs

Shoshie Katz was named Vice President of Quality Assurance and Regulatory Affairs in 2011 having previously served as Director of Quality Assurance and Regulatory Affairs since in 2008., Prior to Chiasma, she established and managed several QA and RA positions with increasing responsibilities at Beta-O2 Technologies Ltd., Proneuron Biotechnologies Ltd., Bio-Technology General (Israel) Ltd. and BioReliance (US). Ms. Katz was responsible for establishing and maintaining Quality Systems in compliance with GMP regulations and leading preparation and submission of IND filings, Orphan Drug applications, and communications with Regulatory Authorities in Israel and in the U.S. Ms. Katz holds an M.S. in Cell Biology and Immunology, Magna Cum Laude, and a B.S. in Life Science from the Faculty of Life Sciences, Tel Aviv University, Israel.

Asi Haviv, D.M.D.

VP Clinical Development

Asi Haviv, D.M.D. joined Chiasma in 2012 as Vice President of Clinical of Development and led the development of MYCAPSSA for acromegaly. Prior to Chiasma, he was a Director at Teva Pharmaceuticals, Global Branded R&D, where he established and led the clinical development strategy of various innovative products in the inflammatory/autoimmune, neurology, and endocrinology therapeutic areas. He also served as a member of the autoimmune search and evaluation team at Teva’s Global Branded Products Business Development group, responsible for the clinical evaluation of in-licensing opportunities. Dr. Haviv brings to Chiasma substantial experience in drug development and interpretation of clinical data together with expertise in due diligence processes and clinical evaluation of product candidate opportunities. He received his Doctor of Dental Medicine (D.M.D) from the Hadassah School of Dental Medicine, the Hebrew University of Jerusalem, where he also completed his residency to become a board-certified oral medicine specialist.

Lee Giguere

VP General Counsel

Lee Giguere, J.D., joined Chiasma in September 2019 as Vice President of General Counsel. Prior to Chiasma, Mr. Giguere worked at Karyopharm Therapeutics, Inc. an oncology-focused pharmaceutical company, where he served as Deputy General Counsel and Assistant Secretary and was responsible for a broad set of corporate legal matters. During his time at Karyopharm, the company filed a new drug application for its cancer drug, XPOVIO^®, obtained accelerated approval from the FDA, and launched the commercial sale of XPOVIO^® in the U.S. Prior to joining Karyopharm, Mr. Giguere was Senior Securities and Governance Counsel at Boston Scientific Corporation, a Fortune 500 medical device company, where he co-led the legal team responsible for public disclosures, SEC and stock exchange compliance, and corporate governance matters. Mr. Giguere began his professional career in the business law department of Goodwin Procter LLP where he focused on representing public companies in connection with securities law compliance, corporate governance and corporate finance transactions. Mr. Giguere earned his B.S. in Finance from Northeastern University and his J.D. from Northeastern University School of Law.

Drew Enamait

VP Finance & Administration

Drew Enamait was named Vice President of Finance & Administration and principal accounting officer in November 2016, having previously served as our Corporate Controller since October 2015. Prior to joining Chiasma, he served in various roles of increasing responsibility culminating in the position of Senior Controller, of LeMaitre Vascular, Inc. (NASDAQ: LMAT), a public medical device company. He also served as a business unit Finance Director and the Manager of Internal Audit at Thermo Fisher Scientific, Inc. (NASDAQ: TMO). Mr. Enamait began his professional career at Arthur Andersen LLP. Mr. Enamait received his B.S. in Accountancy, minor in Law from Bentley College and earned a Certified Public Accountant certificate in the State of Connecticut.

Derek Brown

VP Marketing

Derek Brown joined Chiasma as our Vice President of Marketing in September 2019. Prior to joining Chiasma, Mr. Brown served as consultant at clinical-stage biopharmaceutical companies where he partnered with executive leadership teams to shape the commercialization strategies in rare and ultra-rare diseases. Previously, Mr. Brown worked at Alexion where he led a global team responsible for the commercialization of Ultomiris^®in two ultra-rare hematology diseases (PNH and aHUS) and for the global marketing of Soliris^®, serving patients with PNH, a $2B market opportunity. Prior to Alexion, he worked for 12 years with increasing responsibilities at Boehringer Ingelheim in the U.S. and Germany in product launch, new product planning, marketing, and managed markets roles. Mr. Brown began his career as a management consultant at Accenture. He holds a B.A. in Cellular Structure and Function and in Economics from Middlebury College and an M.B.A. from The Tuck School of Business at Dartmouth.

Mark J. Fitzpatrick

President

Mark J. Fitzpatrick has been our President since June 2019 after serving as both our President and Chief Executive Officer since September 2016. Mark joined Chiasma as its Chief Financial Officer in June 2015. Prior to joining Chiasma, he was Chief Financial Officer at Aegerion Pharmaceuticals, Inc., a biopharmaceutical company specializing in the treatment of rare diseases, from May 2011 to June 2015. From July 2007 to April 2011, Mr. Fitzpatrick served as Chief Financial Officer of Proteon Therapeutics, Inc. (NASDAQ: PRTO), a biopharmaceutical company. He also held the position of Chief Financial Officer at RenaMed Biologics, Inc., Dynogen Pharmaceuticals, Inc., WorldStreet Corporation, and Diacrin, Inc., and has more than 25 years of operational and financial management experience in both public and private companies. Mr. Fitzpatrick began his professional career at Arthur Andersen LLP. Mr. Fitzpatrick received his B.S. in Accounting from Boston College in 1984 and earned a Certified Public Accountant certificate in the Commonwealth of Massachusetts in 1987.

Learn more about

Our Values

Our Values

Persistence

Passion for Results

Ingenuity

Commitment to People

Sense of Urgency

Management Team

Raj Kannan

William Ludlam, M.D., Ph.D.

Anand Varadan

John Doyle

Drew Enamait

Lee Giguere

Shoshie Katz

Gary Patou, M.D.

David Schubert

Board of Directors

Dave Stack

Raj Kannan

Todd Foley

Bard Geesaman, M.D., Ph.D.

Roni Mamluk, Ph.D.

Scott Minick

John A. Scarlett, M.D.

John F. Thero